Applications: |
Immunodepletion/Immunocompetition |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
PDE10A Blocking Peptide for STJ502201 is synthetically produced from the 250-325 sequence and is suitable for use in western blot applications. |
Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Gene Symbol: |
PDE10A |
Gene ID: |
10846 |
Uniprot ID: |
PDE10_HUMAN |
Immunogen Region: |
250-325 |
Specificity: |
This blocking peptide is recommended for use in combination with PDE10A antibody, STJ502201 |
Immunogen: |
Synthetic peptide (Human) taken against a common sequence near the 250-325 amino acids downstream of N terminal region of PDE10A. Synthetic MAP. |
Tissue Specificity | Abundant in the putamen and caudate nucleus regions of brain and testis, moderately expressed in the thyroid gland, pituitary gland, thalamus and cerebellum. |
Post Translational Modifications | Isoform PDE10A2: Phosphorylated on Thr-16. |
Function | Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate. May play a critical role in regulating cAMP and cGMP levels in the striatum, a region of the brain that contributes to the control of movement and cognition. |
Peptide Name | Camp And Camp-Inhibited Cgmp 3' -5'-Cyclic Phosphodiesterase 10a |
Database Links | Reactome: R-HSA-418457Reactome: R-HSA-418555 |
Cellular Localisation | CytoplasmCytosol |
Alternative Peptide Names | Camp And Camp-Inhibited Cgmp 3' -5'-Cyclic Phosphodiesterase 10a proteinPDE10A protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance